Visualitza per autor "Zalcberg, John"
Ara mostrant els elements 1-4 d 4
-
Clinical Activity of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumor Harboring Heterogeneous KIT/PDGFRA Mutations in the Phase III INVICTUS Study
Bauer, Sebastian; Heinrich, Michael C.; Serrano Garcia, César; Gelderblom, Hans; George, Suzanne; Zalcberg, John (American Association for Cancer Research, 2021-12-01) -
Metastatic Colorectal Cancer Outcomes by Age Among ARCAD First- and Second-Line Clinical Trials
McCleary, Nadine Jackson; Harmsen, William; Haakenstad, Ellana; Cleary, J. M.; Meyerhardt, Jeffrey; Tabernero Caturla, Josep; Zalcberg, John (Oxford University Press, 2022-04) -
Patient-reported outcomes and tolerability in patients receiving ripretinib versus sunitinib after treatment with imatinib in INTRIGUE, a phase 3, open-label study
Gelderblom, Hans; Jones, Robin; Blay, Jean-Yves; George, Suzanne; von Mehren, Margaret ; Zalcberg, John; Serrano, Cesar (Elsevier, 2023-07-20) -
Patient-reported outcomes in individuals with advanced gastrointestinal stromal tumor treated with ripretinib in the fourth-line setting: analysis from the phase 3 INVICTUS trial
Schöfski, Patrick; Heinrich, Michael C.; Bauer, Sebastian; Serrano Garcia, César; Gelderblom, Hans; George, Suzanne; Zalcberg, John (BMC, 2022-12-13)